Analytical Chemistry
Cure8 research brief
Why This Matters
Researchers have developed a protease-activated fluorescent nanoprobe that can distinguish early versus late-stage inflammation in a mouse colitis model and can also be measured in feces. If validated in humans, a tool like this could offer a noninvasive way to monitor disease stage in IBD.
Who Should Pay Attention
Researchers, imaging scientists, translational clinicians interested in IBD diagnostics
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This paper reports a laboratory-designed near-infrared (NIR) “turn-on” nanoprobe (IR780 NP@S100) that is activated by granzyme A (GzmA), a protease the authors link to inflammatory bowel disease (IBD).
The nanoprobe is engineered to stay intact in the stomach and release in the colon; when GzmA is present it disassembles and lights up, allowing stage-dependent imaging in a mouse model of acute colitis and fecal fluorescence measurement.
The study is preclinical: experiments were performed in DSS-induced mouse models and describe imaging and fecal-fluorescence readouts rather than human testing. The authors suggest potential future clinical application for stage-differential imaging, but no clinical data are presented.
If you follow IBD research, this is an example of a biomarker-driven imaging probe designed to noninvasively report inflammatory stage in the colon; it may inform future diagnostic tools but is not an available test or treatment now.
Keep In Mind
Preclinical animal study using DSS-induced colitis; findings are preliminary and not yet tested in humans.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationAnalytical Chemistry
AuthorsXinru Kong, Junya Zhang, Qiaochu Jiang +3 more
InstitutionSoutheast University
Study typeArticle
Indexed viaOpenAlex
Source typeResearch paper
PublishedSep 23, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
"Turn-On" Nanoprobe for Stage-Differential Imaging of Inflammatory Bowel Disease.
A colon-targeted, enzyme-activated imaging probe could help distinguish early versus late inflammatory stages in IBD and provide a noninvasive fecal fluorescence signal—potentially improving disease monitoring beyond...
Oral renal-clearable gold supraclusters for near-infrared II urinary diagnosis of ulcerative colitis.
The study describes a new urine-based fluorescent biosensor that detected inflamed intestinal sites and tracked treatment response earlier and more sensitively than fecal calprotectin in a mouse model of IBD, which could...
Monitoring Crohn's Disease After Surgery with Fecal Calprotectin - Physician's Weekly
People with Crohn's disease who have an ileostomy need reliable, noninvasive tools to monitor for postoperative small-bowel inflammation. This study suggests fecal calprotectin measured from ileostomy output may help...